Clinical trial · Interventional
Safe Anastomosis Feasibility Study
Safe Anastomosis Feasibility Study: a Study to Investigate the Efficacy, Mechanism of Action and Safety of the Colovac+ Colorectal Anastomosis Protection Device
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A clinical trial to assess the efficacy, mechanism of action and safety of the Colovac+ Colorectal Anastomosis Protection Device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anastomosis | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Colovac | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Colovac
- description
- Patients receive Colovac device during colorectal surgery
- interventionNames
- Device: Colovac
Primary outcomes (1)
- measure
- To measure the incidence of serious adverse events related to using the device
- timeFrame
- 3 months
- description
- The primary endpoint will be a measurement of SAEs probably related or causaly related to the use of the investigational device, to the index surgery in this clinical trial.
Secondary outcomes (11)
- measure
- To measure the number of participants with evidence of absence of feces between the sheath and the colonic wall before device retrieval
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (18 years of age or older) * Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for malignancy, based on multidisciplinary team recommendations. * Willingness to comply with Clinical Investigation Plan-specific treatment and study visits and to sign a written Informed Consent Form Exclusion Criteria: \- Preoperatively : 1. Patient with inflammatory bowel disease 2. Known allergy to nickel or other components of the Colovac+ kit 3. Pregnant or nursing female subject 4. Concomitant major surgical procedure in combination with Colorectal resection (i.e. hepatectomy) 5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo Clinical Investigation Plan described procedures or interfere with the interpretation of study results. including, but not limited to: 1. COVID-19 positive (active infection) based on test within 72 hours prior to surgery 2. Metastatic disease - unless previously treated with chemotherapy and resection, and the benefit of exposure to the Colovac device is greater than the risk 1 3. Immunodeficiency (CD4+ count \< 500 CU MM) 4. Systemic steroid therapy within the past 6 months 5. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery 6. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study 7. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis 8. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging 9. Severe Malnutrition defined as 10% weight loss within 3 months prior to enrollment. 6. The subject is currently participating in another investigational drug or device study * Intraoperatively : 7. Anastomosis placement at more than 10cm from anal margin 8. Occurrence of any of the following during the colorectal surgery: 1. Blood loss (\>750 cc) 2. Blood transfusion 3. Any new sign of ischemia 4. Positive air leak test - requiring re intervention on the anastomosis 5. Inadequate bowel preparation 6. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device
References
Publications (1)
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
Patricia Sylla, Katherine Lam, Niels Komen et al. · Ann Surg · Sep 2, 2026 · PMID 42681563 pubmed
- DERIVEDSylla P, Lam K, Komen N, Tuech JJ, Spinelli A, Martz J, Rhee R, Marcet J, Cadiere GB, Rouanet P, Karachun A, Denost Q, Sametdinov N, D'Hoore A, Lee S, Lefevre JH. Safety and Performance of the Colovac Anastomosis Protection Device. A Pooled Analysis of Prospective Studies Compared With Diverting Loop Ileostomy (SAFE-2025). Ann Surg. 2026 Sep 2. doi: 10.1097/SLA.0000000000007171. Online ahead of print. PMID 42681563
- DERIVEDDe Hous N, D'Urso A, Cadiere GB, Cadiere B, Rouanet P, Komen N, Lefevre JH. Evaluation of the SafeHeal Colovac+ anastomosis protection device after low anterior resection for rectal cancer: the safe anastomosis feasibility evaluation (SAFE) 2019 trial. Surg Endosc. 2023 Sep;37(9):7385-7392. doi: 10.1007/s00464-023-10272-x. Epub 2023 Jul 18.